Zai Lab Announces Upcoming Presentations in November Investor Conferences
SHANGHAI and SAN FRANCISCO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced that management from Zai Lab will present at the following upcoming virtual investor conferences in November. Details are as follows:
Citi China Investor Conference 2020
Presentation: Thursday, November 5, 2020 at 1:00 p.m. HKT
BioCentury 7th China Healthcare Summit
Panel Discussion: Thursday, November 12, 2020 at 2:00 p.m. HKT
23rd Nomura Investment Forum 2020
Presentation: Thursday, November 12, 2020 at 2:30 p.m. HKT
Goldman Sachs Asia Pacific Healthcare Forum 2020
Panel Discussion: Tuesday, November 17, 2020 at 10:00 a.m. HKT
Jefferies Virtual London Healthcare Conference
Presentation: Wednesday, November 18, 2020 at 10:00 a.m. GMT
A live webcast of the Jefferies Virtual London Healthcare Conference presentation will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. An archived replay will be available for 90 days following the event.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China’s pharmaceutical market and address unmet medical needs, Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.
For additional information about the company, please visit or follow us at /ZaiLab_Global.
For more information, please contact:
ZAI LAB CONTACTS:
Zai Lab
Billy Cho, CFO
01
Media: Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006 ext. 315 / 364
/
Investors: Pete Rahmer / Mike Zanoni
Endurance Advisors, on behalf of Zai Lab
415-515-9763 / 610-442-8570
/
Zai Lab Limited
Source: Zai Lab Limited
